Drug Trial Radar · NCT03903835
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Apr 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Feb 1, 2019
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Karolinska InstitutetAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Swedish Research Council; Kom Op Tegen Kanker; Janssen Pharmaceutica N.V., Belgium; AstraZeneca; Cancerfonden
- First posted
- Apr 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ProBio is an international, outcome-adaptive, multi-arm, open-label, multiple assignment randomized biomarker driven platform trial in patients with metastatic prostate cancer. Patients will be randomized to control or experimental treatment arms. Patients in the control arm will receive standard of care following national guidelines. Patients in the experimental arm will be randomized to treatments based on a biomarker signature inferred from diagnostic tissue or liquid biopsy profiling. The predefined biomarker signatures are tumor properties or mutations in genes/pathways with previously demonstrated clinical validity (e.g. prognostic value or association with treatment response). The biomarker signatures are identified using a hybridisation capture gene panel specifically designed for prostate cancer.
Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Enzalutamide Oral CapsuleDrug
Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Abiraterone Oral TabletDrug
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
CarboplatinDrug
Carboplatin will be administered every 3rd week with an AUC (area under curve) = 5 with a dose calculated according to the Carboplatin AUC Dose calculation (Calvert formula):Dose (mg) = TargetAUC (mg/ml x min) x \[GFR ml/min + 25\].
Cabazitaxel 60 mg Solution for InjectionDrug
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Docetaxel Injectable SolutionDrug
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Radium Chloride Ra-223Drug
Detailed conditions for the use of the study treatment including dose and dosages are described in accordance with the marketing authorisation in the SmPC.
Niraparib plus Abiraterone acetate plus PrednisoneDrug
Niraparib and Abiraterone acetate will be provided by Janssen and will be provided either as a fixed dose combination or as single agents. Detailed use of the study treatment including dose and dosages are described in the Investigator's brochures and SmPC.
Capivasertib plus DocetaxelDrug
Capivasertib is provided by AstraZeneca and will be given in combination with Docetaxel. All subjects will be given up to ten 21-day docetaxel cycles. All subjects will receive Capivasertib, which will be administered as tablets taken twice a day orally, on a 4 days on/3 days off continuous schedule, commencing cycle one, day 2, until disease progression.
ApalutamideDrug
Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
DarolutamideDrug
Detailed conditions for the use of the study treatments including dose and dosages are described in accordance with the marketing authorization in the SmPC (Summary of Product Characteristics).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS) in mCRPCTime frame: Until progressive disease or 60 months from start of treatment, whatever occurs first.
- Progression free survival (PFS) in mHSPCTime frame: From date of treatment start until the date of first documentation of progression, assessed up to 60 months
Locations
32 sites in 4 countries. Site status is shown where the registry gives one.
OLV Ziekenhuis Aalst
Aalst, Belgium · Recruiting
GZA Sint-Augustinus
Antwerp, Belgium · Recruiting
AZ Sint-Jan AV
Bruges, Belgium · Recruiting
AZ Sint-Lucas
Bruges, Belgium · Recruiting
Ziekenhuis Oost-Limburg
Genk, Belgium · Recruiting
University Hospital Ghent
Ghent, Belgium · Recruiting
AZ Jan Palfijn Ziekenhuis
Ghent, Belgium · Not yet recruiting
Jessa ziekenhuis
Hasselt, Belgium · Recruiting
AZ Groeninge
Kortrijk, Belgium · Recruiting
University Hospital Luik
Liège, Belgium · Recruiting
AZ Damiaan
Ostend, Belgium · Recruiting
VITAZ
Sint-Niklaas, Belgium · Recruiting
Ålesund Sjukehus
Ålesund, Norway · Not yet recruiting
Kreftsenter Kristiansand
Kristiansand, Norway · Recruiting
Akershus Universitetssykehus
Lørenskog, Norway · Recruiting
Stavanger Universitetssjukehus
Stavanger, Norway · Recruiting
Universitetssykehuset Nord-Norge Tromsö
Tromsø, Norway · Not yet recruiting
Södra Alvsborgs sjukhus
Borås, Sweden · Recruiting
Länssjukhuset Ryhov - Onkologiska kliniken
Jönköping, Sweden · Recruiting
Länssjukhuset
Kalmar, Sweden · Recruiting
Centralsjukhuset Region Värmland
Karlstad, Sweden · Recruiting
Universitetssjukhuset Örebro
Örebro, Sweden · Recruiting
Karolinska University Hospital
Stockholm, Sweden · Recruiting
Capio St.Görans Hospital
Stockholm, Sweden · Recruiting
Länssjukhuset Sundsvall Härnösand
Sundsvall, Sweden · Recruiting
Norrlands Universitetssjukhus
Umeå, Sweden · Recruiting
Akademiska sjukhuset
Uppsala, Sweden · Recruiting
Hallands sjukhus Varberg
Varberg, Sweden · Recruiting
Centrallasarettet Onkologkliniken
Vaxjo, Sweden · Recruiting
Falu lasarett
Falun, Region Dalarna, Sweden · Recruiting
St. Claraspital
Basel, Switzerland · Recruiting
Universitätsspital Basel
Basel, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.